London, UK -- (MARKET WIRE) -- November 14, 2006 --

For Immediate Release                                   14 November, 2006

                                 SkyePharma PLC

LONDON, ENGLAND, 13 November 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces today that Mr. Donald Nicholson is standing down as Finance Director with immediate effect and will be leaving the Company to pursue a new phase in his career. Mr. Peter Grant has been appointed Finance Director in his place.

Peter, 51, is a Chartered Accountant with a MA (Hons), Mathematics from Oxford University. He qualified with the firm of Peat, Marwick, Mitchell & Co. in 1979. With over 25 years of finance and management experience in UK companies, including nine years at listed company board level, Peter brings extensive experience as a Finance Director at Molins PLC, Worldpay Group PLC and Eurodis Electron PLC where he worked as Group Finance Director until January 2005. Most recently, Peter had been interim CEO at Voice Commerce Group, a position he held until May 2006.

Donald joined SkyePharma in February 1996 and was appointed Finance Director in March 1997.

Jerry Karabelas, Chairman of SkyePharma, said:

"On behalf of the whole Board and staff, I would like to thank Donald for his significant contribution and commitment to the Company over the past ten years. We wish him well for the future.

"We are very pleased to have recruited someone of Peter's calibre to fill the key role of Finance Director. He has played a significant role in streamlining operations, developing new business activities and financing initiatives. He will join our new management team of Frank Condella, CEO and Ken Cunningham, COO and will be of great assistance in moving the Company forward through this important stage in its development."

Disclosure under section 9.6.13 of the Listing Rules:

Mr Grant resigned from the board of Eurodis Electron PLC in January 2005 for family health reasons. In March 2005 a major franchiser gave notice of termination of its relationship with the group, and in July 2005 the lead finance provider reduced the facilities and the company went into administration.

There are no other disclosures under section 9.6.13 of the Listing Rules.

For further information please contact:

SkyePharma PLC                                      UK + 44 207 491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer

Buchanan Communications                             UK + 44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich

The Trout Group                                     US + 1 617 583 1308
Seth Lewis

Notes for editors

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit

Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.

                      This information is provided by RNS
            The company news service from the London Stock Exchange